18 January 2016 - The Transparency Commission will consider the reimbursement of dronedarone hydrochloride (Multaq), palonosetron hydrochloride (AloxI), lanreotide acetate (Somatuline), alfa-1 anti-trypsin (human) (Respreeza) and cholic acid (Kolbam).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/ordre_du_jour_ct_20012016_internet.pdf [French]